Immunome (IMNM) Accumulated Expenses (2019 - 2026)

Immunome's Accumulated Expenses history runs 8 years deep, the most recent figure standing at $3.1 million for Q1 2026.

• Quarterly Accumulated Expenses fell 82.62% year-over-year to $3.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.1 million (down 82.62% YoY) and the FY2025 annual result came in at $41.7 million, up 610.65% from the prior year.
• Accumulated Expenses was $3.1 million for Q1 2026 at Immunome, down from $41.7 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $41.7 million in Q4 2025 and bottomed at $827000.0 in Q1 2023.
• A 5-year average of $10.0 million and a median of $5.0 million in 2023 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2023 — Accumulated Expenses tumbled 85.78% — and 2024, when it soared 1812.2%.
• Immunome's Accumulated Expenses stood at $4.9 million in 2022, then sank by 44.55% to $2.7 million in 2023, then surged by 114.37% to $5.9 million in 2024, then soared by 610.65% to $41.7 million in 2025, then plunged by 92.63% to $3.1 million in 2026.
• Business Quant data shows IMNM's Accumulated Expenses at $3.1 million in Q1 2026, $41.7 million in Q4 2025, and $7.2 million in Q3 2025.